Open AccessDOI
Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD)
Paria Zarghamravanbakhsh,Michael Frenkel,Leonid Poretsky +2 more
- Vol. 12, pp 100149
Reads0
Chats0
TLDR
In this paper, the etiology of lean NAFLD, the impact of obesity, type 2 diabetes mellitus (T2DM), genetics, and microbiome dysbiosis are explored.Abstract:
Nonalcoholic Fatty Liver Disease (NAFLD) is a multifactorial metabolic disorder that was first described in 1980. It has been prevalent and on the rise for many years and is associated with other metabolic disorders such as obesity and type 2 diabetes mellitus (T2DM). NAFLD can be best described as a metabolic dysfunction that stems from insulin resistance-induced hepatic lipogenesis. This lipogenesis increases oxidative stress and hepatic inflammation and is often potentiated by genetic and gut microbiome dysfunction. As NAFLD progresses from simple steatosis to non-alcoholic steatohepatitis (NASH) and to cirrhosis and hepatocellular carcinoma (HCC), the odds of complications including cardiovascular disease (CVD), chronic kidney disease (CKD), and overall mortality increase. The aim of this review is to describe the metabolic causes and consequences of NAFLD while examining the risks that each stage of NAFLD poses. In this review, the etiology of “lean” NAFLD, the impact of obesity, T2DM, genetics, and microbiome dysbiosis on NAFLD progression are all explored. This review will also discuss the core issue behind the progression of NAFLD: insulin resistance (IR). Upon describing the causes and consequences of NAFLD, the effectiveness of diet modification, lifestyle changes, and glucagon-like peptide 1 receptor (GLP-1) agonists to retard NAFLD progression and stem the rate of complications is examined.read more
Citations
More filters
Journal ArticleDOI
Association of Nonalcoholic Fatty Liver Disease With COVID-19 Severity and Pulmonary Thrombosis: CovidFAT, a Prospective, Observational Cohort Study
Nina Vrsaljko,Lara Šamadan,Klaudija Višković,Armin Mehmedović,Jelena Budimir,Adriana Vince,Neven Papic +6 more
TL;DR: NAFLD is associated with higher COVID-19 severity, more adverse outcomes, and more frequent pulmonary thrombosis, and was identified as a risk factor for pulmonary thROMbosis.
Journal ArticleDOI
Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future
João Paulo Margiotti Dos Santos,Mariana Canevari de Maio,Monike Alves Lemes,Lucas Fornari Laurindo,Jesselina Francisco dos Santos Haber,Marcelo Dib Bechara,Pedro Sidnei do Prado,Eduardo Costa Rauen,Fernando Teixeira Costa,Barbara Cristina de Abreu Pereira,Uri Adrian Prync Flato,Ricardo de Alvares Goulart,Eduardo Federighi Baisi Chagas,Sandra Maria Barbalho +13 more
TL;DR: Further studies involving skeletal muscle, adipose, bone, and liver tissue as endocrine organs are essential to better understand the modulation of organokines involved in the pathogenesis of NASH to advance in the treatment of this disease.
Journal ArticleDOI
Insulin Clearance in Health and Disease.
TL;DR: The evidence suggesting a pathogenic role for reduced insulin clearance in insulin resistance, obesity, hepatic steatosis, and type 2 diabetes is considered.
Journal ArticleDOI
Could gut mycobiome play a role in NAFLD pathogenesis? Insights and therapeutic perspectives
TL;DR: In this paper , the authors characterized the fecal mycobiome of patients with NAFLD and controls, and found that in subjects with NASH and advanced fibrosis, there was an augmented systemic immune response to Candida albicans.
References
More filters
Journal ArticleDOI
Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Journal ArticleDOI
Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
Jeffrey D. Browning,Lidia S. Szczepaniak,Robert L. Dobbins,Pamela Nuremberg,Jay D. Horton,Jonathan Cohen,Scott M. Grundy,Helen H. Hobbs +7 more
TL;DR: The prevalence of hepatic steatosis was greater in men than women among whites, but not in blacks or Hispanics, and significant ethnic and sex differences in the prevalence may have a profound impact on susceptibility to Steatosis‐related liver disease.
Journal ArticleDOI
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
Christi A. Matteoni,Zobair M. Younossi,Terry Gramlich,Navdeep Boparai,Yao Chang Liu,Arthur J. McCullough +5 more
TL;DR: The outcome of cirrhosis and liver-related death is not uniform across the spectrum of nonalcoholic fatty liver, and poor outcomes are more frequent in patients in whom biopsies show ballooning degeneration and Mallory hyaline or fibrosis.
Journal ArticleDOI
Autophagy regulates lipid metabolism
Rajat Singh,Susmita Kaushik,Yongjun Wang,Youqing Xiang,Inna Novak,Masaaki Komatsu,Keiji Tanaka,Ana Maria Cuervo,Mark J. Czaja +8 more
TL;DR: A previously unknown function for autophagy in regulating intracellular lipid stores (macrolipophagy) is identified that could have important implications for human diseases with lipid over-accumulation such as those that comprise the metabolic syndrome.
Journal ArticleDOI
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair M. Younossi,Quentin M. Anstee,Milena Marietti,Timothy Hardy,Timothy Hardy,Linda Henry,Mohammed Eslam,Jacob George,Elisabetta Bugianesi +8 more
TL;DR: The large number of patients with NAFLD with potential for progressive liver disease creates challenges for screening, as the diagnosis of NASH necessitates invasive liver biopsy.